547 related articles for article (PubMed ID: 26603736)
1. Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients.
Mele D; Malagutti P; Indelli M; Ferrari L; Casadei F; Da Ros L; Pollina A; Fiorencis A; Frassoldati A; Ferrari R
Ultrasound Med Biol; 2016 Jan; 42(1):125-32. PubMed ID: 26603736
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.
Keramida K; Farmakis D; Bingcang J; Sulemane S; Sutherland S; Bingcang RA; Ramachandran K; Tzavara C; Charalampopoulos G; Filippiadis D; Kouris N; Nihoyannopoulos P
Eur J Heart Fail; 2019 Apr; 21(4):529-535. PubMed ID: 30811091
[TBL] [Abstract][Full Text] [Related]
3. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.
Tan TC; Bouras S; Sawaya H; Sebag IA; Cohen V; Picard MH; Passeri J; Kuter I; Scherrer-Crosbie M
J Am Soc Echocardiogr; 2015 May; 28(5):509-14. PubMed ID: 25772019
[TBL] [Abstract][Full Text] [Related]
4. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Trastuzumab-induced early cardiac dysfunction using two-dimensional Strain Echocardiography.
Emren SV; Tuluce SY; Levent F; Tuluce K; Kalkan T; Yildiz Y; Alacacioğlu A; Kucukzeybek Y; Akyol M; Salman T
Med Ultrason; 2015 Dec; 17(4):496-502. PubMed ID: 26649345
[TBL] [Abstract][Full Text] [Related]
6. Deformation Analysis of Myocardial Layers Detects Early Cardiac Dysfunction after Chemotherapy in Bone Marrow Transplantation Patients: A Continuous and Additive Cardiotoxicity Process.
Paraskevaidis IA; Makavos G; Tsirigotis P; Psarogiannakopoulos P; Parissis J; Gkirkas K; Pessach I; Ikonomidis I
J Am Soc Echocardiogr; 2017 Nov; 30(11):1091-1102. PubMed ID: 28864152
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
[TBL] [Abstract][Full Text] [Related]
8. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
9. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study.
Ho E; Brown A; Barrett P; Morgan RB; King G; Kennedy MJ; Murphy RT
Heart; 2010 May; 96(9):701-7. PubMed ID: 20424152
[TBL] [Abstract][Full Text] [Related]
10. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection.
Negishi K; Negishi T; Haluska BA; Hare JL; Plana JC; Marwick TH
Eur Heart J Cardiovasc Imaging; 2014 Mar; 15(3):324-31. PubMed ID: 24057661
[TBL] [Abstract][Full Text] [Related]
11. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy.
Stoodley PW; Richards DA; Hui R; Boyd A; Harnett PR; Meikle SR; Clarke J; Thomas L
Eur J Echocardiogr; 2011 Dec; 12(12):945-52. PubMed ID: 21965152
[TBL] [Abstract][Full Text] [Related]
12. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Clarke JL; Thomas L
Eur Heart J Cardiovasc Imaging; 2013 Mar; 14(3):228-34. PubMed ID: 22782955
[TBL] [Abstract][Full Text] [Related]
13. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study.
Boyd A; Stoodley P; Richards D; Hui R; Harnett P; Vo K; Marwick T; Thomas L
PLoS One; 2017; 12(4):e0175544. PubMed ID: 28407011
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
15. Use of echocardiography to monitor myocardial damage during anthracycline chemotherapy.
Anqi Y; Yu Z; Mingjun X; Xiaoli K; Mengmeng L; Fangfang L; Mei Z
Echocardiography; 2019 Mar; 36(3):495-502. PubMed ID: 30636342
[TBL] [Abstract][Full Text] [Related]
16. Subclinical Myocardial Impairment Occurred in Septal and Anterior LV Wall Segments After Anthracycline-Embedded Chemotherapy and did not Worsen During Adjuvant Trastuzumab Treatment in Breast Cancer Patients.
Lange SA; Jung J; Jaeck A; Hitschold T; Ebner B
Cardiovasc Toxicol; 2016 Apr; 16(2):193-206. PubMed ID: 26022230
[TBL] [Abstract][Full Text] [Related]
17. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
18. Single Versus Standard Multiview Assessment of Global Longitudinal Strain for the Diagnosis of Cardiotoxicity During Cancer Therapy.
Thavendiranathan P; Negishi T; Coté MA; Penicka M; Massey R; Cho GY; Hristova K; Vinereanu D; Popescu BA; Izumo M; Negishi K; Marwick TH;
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1109-1118. PubMed ID: 29778856
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
20. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
